Medicine and Dentistry
Bladder Cancer
100%
Non Muscle Invasive Bladder Cancer
59%
Neoplasm
52%
Transitional Cell Carcinoma
31%
Bacilli
25%
Cystectomy
24%
Muscle Invasive Bladder Cancer
23%
Recurrent Disease
23%
Systematic Review
22%
Radiation Therapy
22%
Cisplatin
22%
Bladder
20%
Cystoscopy
18%
Diseases
18%
Clinical Trial
17%
Biological Marker
16%
Immunotherapy
14%
Microhematuria
13%
Urothelial Cancer
13%
Upper Urinary Tract
12%
Urology
12%
Pathologist
12%
Retroperitoneal Lymph Node Dissection
12%
Fibroblast Growth Factor Receptor 3
11%
Surgical Margin
11%
COVID-19
11%
Chemoimmunotherapy
11%
Protein P53
11%
Seminoma
11%
Cancer Survival
11%
Urinary System
11%
Surveillance System
11%
Diagnostic Accuracy
11%
Invasive Bladder Cancer
11%
Kidney Cancer
11%
Digital Pathology
11%
Health Outcomes
11%
Programmed Death-Ligand 1
11%
Mesothelioma
11%
Tissue (Anatomy)
9%
Urinary Tract
8%
Disease Specific Survival
8%
Adjuvant Therapy
8%
Bladder Cancer Diagnosis
7%
Kidney Metastasis
7%
Bladder Muscle
7%
Immune Checkpoint Inhibitor
7%
Neoadjuvant Chemotherapy
7%
Progression Free Survival
6%
Diagnosis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Muscle Invasive Bladder Cancer
59%
Bladder Cancer
55%
Neoplasm
33%
Mycobacterium Bovis BCG
22%
Biological Marker
16%
Bacilli
14%
Muscle Invasive Bladder Cancer
14%
Respiratory Tract Infection
11%
Fibroblast Growth Factor Receptor 3
11%
Protein P53
11%
Digital Pathology
11%
Cisplatin
11%
Mesothelioma
11%
Transitional Cell Carcinoma
11%
Kidney Cancer
11%
Recurrent Disease
10%
Chemotherapy
8%
Immune Checkpoint Inhibitor
7%
Kidney Metastasis
7%
Hematuria
5%
Rare Disease
5%
Biochemistry, Genetics and Molecular Biology
Cisplatin
18%
Bacilli
14%
Clinical Trial
11%
Mitogen-Activated Protein Kinase
11%
DNA Damage Response
11%
Gene Signature
11%
Turnaround Time
11%
Artificial Intelligence
11%
PD-L1
11%
DNA Sequence
11%
High Risk Population
11%
Mycobacterium Bovis BCG
11%
Urine Sampling
11%
Cell Cycle
11%
P53
11%
Digital Pathology
11%
Immune Checkpoints
7%
Disease Specific Survival
6%
HRAS
5%
Survival Prediction
5%
Methylation
5%